Intelligence Feed event · Equity · 2026-09-03

    Nxera Pharma Secures $8.6M Milestone from Centessa on OX2R Agonist Progress

    Question

    Nxera Pharma Secures $8.6M Milestone from Centessa on OX2R Agonist Progress

    Direct answer

    Nxera Pharma announced the receipt of an $8.6 million milestone payment from Eli Lilly subsidiary Centessa Pharmaceuticals following late-stage clinical progress on selective orexin receptor 2 (OX2R) agonist candidates. Nxera will recognize the payment directly in its Q3 2026 revenue while maintaining royalty and commercial rights linked to the program.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Nxera Pharma Secures $8.6M Milestone from Centessa on OX2R Agonist Progress”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/nxera-pharma-secures-8-6m-milestone-from-centessa-on-ox2r-agonist-progress-b112dc

    EQUITY
    Nxera Pharma Secures $8.6M Milestone from Centessa on OX2R Agonist Progress
    Nxera Pharma announced the receipt of an $8.6 million milestone payment from Eli Lilly subsidiary Centessa Pharmaceuticals following late-stage clinical progress on selective orexin receptor 2 (OX2R) agonist candidates. Nxera will recognize the payment directly in its Q3 2026 revenue while maintaining royalty and commercial rights linked to the program.
    LLY
    Impact
    60
    SEP 3
    SIG
    85%
    LLY
    Nxera Pharma Secures $8.6M Milestone from Centessa on OX2R Agonist Progress
    Nxera Pharma announced the receipt of an $8.6 million milestone payment from Eli Lilly subsidiary Centessa Pharmaceuticals following late-stage clinical progress on selective orexin receptor 2 (OX2R) agonist candidates. Nxera will recognize the payment directly in its Q3 2026 revenue while maintaining royalty and commercial rights linked to the program.
    → Direct pipeline milestone recognition adds $8.6M in high-margin licensing revenue to Nxera while validating Eli Lilly's OX2R clinical pipeline.
    Impact
    Nxera Pharma announced the receipt of an $8.6 million milestone payment from Eli Lilly subsidiary Centessa Pharmaceuticals following late-stage clinical progress on selective orexin receptor 2 (OX2R) agonist candidates. Nxera will recognize the payment directly in its Q3 2026 revenue while maintaining royalty and commercial rights linked to the program.
    Affected
    LLY
    Transmission
    Direct pipeline milestone recognition adds $8.6M in high-margin licensing revenue to Nxera while validating Eli Lilly's OX2R clinical pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYclinical pipeline advancement in selective orexin receptor agonistsUp1-4wCentessa Pharmaceuticals, a subsidiary of Eli Lilly, achieved late-stage progress on OX2R candidates.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month